Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
breakout alert $BRNE
breakout alert $BRNE
breakout alert $BRNE
breakout alert $BRNE
$BRNE 0.0012 gone. Spread tight. Breakout coming!
$BRNE 0.0012 gone. Spread tight. Breakout coming!
get some instead of chasing the rocket! $BRNE might be your lifechanger
$BRNE on close watch for volume and breakout! . CEO runs second company successfully $EAIAF. Merger rumor about BRNE. Market cap under 400k and locked float.
$BRNE on close watch for volume and breakout! . CEO runs second company successfully $EAIAF. Merger rumor about BRNE. Market cap under 400k and locked float.
$BRNE on close watch for volume and breakout! . CEO runs second company successfully $EAIAF. Merger rumor about BRNE. Market cap under 400k and locked float.
$UPIN updates next week!
$UPIN We have received many inquiries as to company updates. Due to Covid-19, it has taken time for the company to adjust business operations, we have addressed said and are now moving forward. The company will start issuing updates this week with our annual report by months end.
— Universal Power Industry Corporation (@upinholdings) September 21, 2020
$UPIN updates next week!
$UPIN We have received many inquiries as to company updates. Due to Covid-19, it has taken time for the company to adjust business operations, we have addressed said and are now moving forward. The company will start issuing updates this week with our annual report by months end.
— Universal Power Industry Corporation (@upinholdings) September 21, 2020
$UPIN moving!
$BRNE more information about the CEO's second company $EAIAF to get a clue how much potential we have here at $BRNE!
https://seekingalpha.com/article/4375058-east-asia-minerals-corporation-big-potential-in-long-forgotten-name
$BRNE more information about the CEO's second company $EAIAF to get a clue how much potential we have here at $BRNE!
https://seekingalpha.com/article/4375058-east-asia-minerals-corporation-big-potential-in-long-forgotten-name
$BRNE more information about the CEO's second company $EAIAF to get a clue how much potential we have here at $BRNE!
https://seekingalpha.com/article/4375058-east-asia-minerals-corporation-big-potential-in-long-forgotten-name
Hre you can see an interview with BRNE-CEO talking about his second company $EAIAF
The man knows how to run a business. $BRNE will come to life big times!
lovely chart with locked float! $BRNE little stop at 0.0014 then sky is the limit!
lovely chart with locked float! $BRNE little stop at 0.0014 then sky is the limit!
lovely chart with locked float! $BRNE little stop at 0.0014 then sky is the limit!
This one is screaming for a huge huge breakout! Float seems to be locked. So thin!
$BRNE breakout! Rumor about huge reverse merger!
$BRNE breakout! Rumor about huge reverse merger!
$UPIN rumor about new significant investment In Company From Leading New York Based Institutional Fund
https://twitter.com/RumorMurmurBuzz/status/1305667838779113472?s=19
$UPIN rumor about new significant investment In Company From Leading New York Based Institutional Fund
https://twitter.com/RumorMurmurBuzz/status/1305667838779113472?s=19
$BRNE nice close. Huge merger rumor! CEO owns/runs $EAIAF, too.
$BRNE nice close. Huge merger rumor! CEO owns/runs $EAIAF, too.
$BRNE nice close. Huge merger rumor! CEO owns/runs $EAIAF, too.
$BRNE nice close. Huge merger rumor! CEO owns/runs $EAIAF, too.
Take a short breath, fasten your seatbelt and join the $UPIN rocket! Float locked.
Take a short breath, fasten your seatbelt and join the $UPIN rocket! Float locked.
follow the money! Go $UPIN Acquisition news pending?
follow the money! Go $UPIN Acquisition news pending?
follow the money! Go $UPIN Acquisition news pending?
ALERT $UPIN sudden volume!
ALERT $UPIN sudden volume!
ALERT $UPIN sudden volume!
News out! Go $OBMP
Theralink(R) Technologies Achieves Milestone, CLIA Certification for its Golden, CO Laboratory
Expect to Begin Receiving, Testing and Billing for Patient's Breast Cancer Tumor Specimens in Q4 2020
DENVER, CO / ACCESSWIRE / September 9, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical Laboratory Improvement Amendments (CLIA) certification for its Golden, Colorado laboratory, retroactively effective as of January 8, 2020.
The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the Colorado CLIA Certification Program survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.
"We are thrilled to receive CLIA certification for our Golden, CO laboratory, as this was truly a team effort that began two years ago. Receiving CLIA certification is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights from human trials in cancer treatment," said Mick Ruxin, M.D., President and CEO of Theralink Technologies, Inc. "With CLIA certification, we expect to begin receiving, testing, and billing for patient's breast cancer tumor specimens in the fourth quarter of 2020."
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado, that uniquely specializes in patented, phosphoprotein, and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
News out! Go $OBMP
Theralink(R) Technologies Achieves Milestone, CLIA Certification for its Golden, CO Laboratory
Expect to Begin Receiving, Testing and Billing for Patient's Breast Cancer Tumor Specimens in Q4 2020
DENVER, CO / ACCESSWIRE / September 9, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical Laboratory Improvement Amendments (CLIA) certification for its Golden, Colorado laboratory, retroactively effective as of January 8, 2020.
The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the Colorado CLIA Certification Program survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.
"We are thrilled to receive CLIA certification for our Golden, CO laboratory, as this was truly a team effort that began two years ago. Receiving CLIA certification is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights from human trials in cancer treatment," said Mick Ruxin, M.D., President and CEO of Theralink Technologies, Inc. "With CLIA certification, we expect to begin receiving, testing, and billing for patient's breast cancer tumor specimens in the fourth quarter of 2020."
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado, that uniquely specializes in patented, phosphoprotein, and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
News out! Go $OBMP
Theralink(R) Technologies Achieves Milestone, CLIA Certification for its Golden, CO Laboratory
Expect to Begin Receiving, Testing and Billing for Patient's Breast Cancer Tumor Specimens in Q4 2020
DENVER, CO / ACCESSWIRE / September 9, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical Laboratory Improvement Amendments (CLIA) certification for its Golden, Colorado laboratory, retroactively effective as of January 8, 2020.
The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the Colorado CLIA Certification Program survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.
"We are thrilled to receive CLIA certification for our Golden, CO laboratory, as this was truly a team effort that began two years ago. Receiving CLIA certification is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights from human trials in cancer treatment," said Mick Ruxin, M.D., President and CEO of Theralink Technologies, Inc. "With CLIA certification, we expect to begin receiving, testing, and billing for patient's breast cancer tumor specimens in the fourth quarter of 2020."
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado, that uniquely specializes in patented, phosphoprotein, and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.